Abstract
Ichihashi et al reported that 43% of patients had antipsychotic polypharmacy. Number of antipsychotics used in patients with schizophrenia in Japan was the greatest among Asian countries. However, the antipsychotic polypharmacy rate in Japan decreased gradually. Recent systematic review, meta-analysis and meta-regression analysis demonstrated that antipsychotic augmentation was superior to monotherapy. However, several cohort studies have suggested a significant association between antipsychotic daily dose and mortality. In addition, most pharmacokinetic interactions with antipsychotics occur at the metabolic level and usually involve changes in the activity of the major drug-metabolizing enzymes involved in their biotransformation. Thus, avoidance of unnecessary polypharmacy, knowledge of the interaction profiles of individual agents, and careful individualization of dosage based on close evaluation of clinical response and possibly plasma drug concentrations are essential to prevent and minimize potentially adverse drug interactions in patients receiving antipsychotics.
References
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Feb 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Matti JoukamaaVille Lehtinen
Jul 28, 2006·Psychiatric Services : a Journal of the American Psychiatric Association·Miranda H ChakosRobert A Rosenheck
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Edoardo Spina, Jose de Leon
Jan 16, 2009·The New England Journal of Medicine·Wayne A RayC Michael Stein
Jan 6, 2010·Archives of General Psychiatry·Ramin Mojtabai, Mark Olfson
Sep 4, 2010·Journal of Clinical Psychopharmacology·Norio Yasui-FurukoriSunao Kaneko
Jul 28, 2011·BMC Psychiatry·Fuminari MisawaHaruo Kashima
May 9, 2012·Expert Opinion on Drug Safety·Juan A GallegoChristoph U Correll
May 9, 2012·Archives of General Psychiatry·Jari TiihonenPasi Korhonen
Nov 1, 2012·Schizophrenia Bulletin·Bernadette A CullenGail L Daumit
Nov 28, 2013·Schizophrenia Research·Lajos KatonaIstván Bitter
Nov 26, 2014·Schizophrenia Bulletin·Minna TorniainenJari Tiihonen
Jan 28, 2017·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Britta GallingChristoph U Correll
May 16, 2018·Psychiatry and Clinical Neurosciences·Shu-Yu YangShih-Ku Lin
Sep 4, 2018·Neuropsychopharmacology Reports·Soichiro IdeKazutaka Ikeda
Oct 13, 2018·The Australian and New Zealand Journal of Psychiatry·Hong QiuWentian Dong
Feb 21, 2019·JAMA Psychiatry·Jari TiihonenAntti Tanskanen
Aug 23, 2019·Psychiatry and Clinical Neurosciences·Yoshikazu TakaesuRyota Hashimoto
Citations
Sep 15, 2020·Frontiers in Psychiatry·Gao-Xia WeiQian Yu
Feb 6, 2021·Neuropsychiatric Disease and Treatment·Hiroaki OkayasuKazutaka Shimoda
Jul 4, 2021·Asian Journal of Psychiatry·Mariko TsukijiTomihisa Niitsu
Jul 30, 2021·Asian Journal of Psychiatry·Naoki HashimotoRyota Hashimoto